← All trials
NCT06791070
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Jan 31, 2027
- Completion date
- Jan 31, 2028
- First posted
- Jan 24, 2025
- Last posted
- Jan 24, 2025
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fujian Medical UniversityLead sponsor
- Guangzhou Medical UniversityCollaborator
- Fujian Medical UniversityOfficial
- Fujian Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Fujian Provincial HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.